RxDoctor Payments Data

Jodi Morrisey

Nurse Practitioner · Mattoon, ILNPI 1487948303

Payments from drug & device makers

$1,967in general payments, 2019–2025

Across 95 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$255
  • AstraZeneca$176
  • Astellas Pharma US Inc$171
  • Olympus America Inc.$161
  • Merck$151
  • Coloplast$147
  • plus $905 from 17 others

What the payments were for

  • Food & beverage$1,80492%
  • Education$1638%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,967 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$78,814
Medicare patients
624
Services billed
1,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron704$504,444
MyrbetriqMirabegron213$153,758
Estradiol150$11,760
Tamsulosin Hcl561$9,086
Finasteride474$6,325
Silodosin53$6,210
Solifenacin Succinate109$5,342
Testosterone37$3,987
Tolterodine Tartrate ErTolterodine Tartrate37$3,286
Potassium Citrate ErPotassium Citrate43$3,206
Fesoterodine Fumarate ErFesoterodine Fumarate37$2,321
Alfuzosin Hcl ErAlfuzosin Hcl115$2,101
Trospium Chloride58$1,863
Oxybutynin Chloride ErOxybutynin Chloride81$1,856
Terazosin Hcl48$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$255$504,444704 claims
Astellas Pharma US IncMyrbetriq$171$153,758213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Mattoon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →